lobbying_activities: 1879672

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1879672	52c11390-1aee-4898-85c8-34ad27f6a9c5	Q3	AMERICAN CLINICAL LABORATORY ASSN	1923	AMERICAN CLINICAL LABORATORY ASSN	2016	third_quarter	MED	Reimbursement and coverage issues related to the Medicare Clinical Laboratory Fee Schedule and the Physician Fee Schedule, including implementation of the Protecting Access to Medicare Act (P.L. 113-93) and cost-sharing for clinical laboratory services under Part B; H.R. 6, 21st Century Cures Act; the regulation and oversight of clinical laboratories, including laboratory-developed tests; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; H.R. 2, the Medicare Access and CHIP Reauthorization of 2015; and H.R 4909, the National Defense Authorization Act for Fiscal Year 2017.	Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE		199612	0	0	2016-10-17T14:37:32.477000-04:00